Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Prometheus"


25 mentions found


Photos show how the UAE, United States, and other countries have been seeding clouds for decades. Historic floods in Dubai didn't come from cloud seeding, but humans' climate impacts are playing a role. Related storiesAccording to several scientists, cloud seeding isn't the driving force behind Dubai's historic floods. Packets of salt are pictured during a cloud seeding operation at a military airbase in Subang, Malaysia. The real threat behind Dubai's floodsMany atmospheric scientists have dismissed the idea that cloud seeding was behind Dubai's floods.
Persons: GIUSEPPE CACACE, Getty, Prometheus, Frankenstein —, Thomas Peipert, Al Hayer, Amr Alfiky, Andrea DiCenzo, Lim Huey Teng, there'd, Friederike Otto, John Marsham, Jeff Big Jeff, Gary Coronado, Marsham, Fred Greaves, Otto Organizations: Dubai didn't, Service, United Arab Emirates, United Arab, UAE, Reuters, National Center of Meteorology, United, UAE's National, of Meteorology, Militia, Imperial College London, Science Media, SMC, University of Leeds, Los Angeles Times, Getty, UAE isn't, National Park Service, AP Locations: UAE, United States, Dubai, United Arab Emirates, Rocky, Lyons , Colorado, China, Australia, Al Ain, Utah, Dongkou county, Shaoyang, Hunan province, Subang, Malaysia, Bannon, Sacramento, , California, California's Sacramento County
It was time to smell Scriabin’s “Prometheus: The Poem of Fire.”This music, from 1910, has an element of synesthesia in its score, which calls for a color organ — a keyboard instrument that projects lights of a dozen hues — along with a full orchestra, a piano soloist and a choir. But in October at Davies Symphony Hall, the home of the San Francisco Symphony, the piece was being prepared with an additional sense in mind. Onstage, the pianist Jean-Yves Thibaudet practiced his solo part in “Prometheus,” which the San Francisco Symphony will perform March 1 through 3, while the conductor Esa-Pekka Salonen listened attentively to the wooden vortexes as they were being tested; the sound they made while emitting smoke, he noticed, was nearly a G.Mathilde Laurent, Cartier’s longtime perfumer, who had designed the scents, double-checked notes on her iPad. For this day’s test, without the orchestra, she wanted to be sure the diffusers were timed to match the music. So they were going to play a recording overhead.
Persons: Jean, Yves Thibaudet, Pekka Salonen, attentively, Mathilde Laurent, Cartier’s, perfumer Organizations: Davies Symphony Hall, San Francisco Symphony, San Francisco
Immunovant could emerge as a key player in the autoimmune space, according to JPMorgan. The bank initiated coverage of the biotech stock at an overweight rating, also setting a price target of $51. That implies that shares of Immunovant could rally more than 37% from their Friday closing price of $37.13. Immunovant stock has slid 9% so far this quarter. IMVT YTD mountain IMVT YTD chart As a key catalyst, the analyst underscored Immunovant's stats as one of the key players using anti-neonatal Fc receptor technology, or anti-FcRn technology, to treat autoimmune diseases.
Persons: Brian Cheng, Graves, Cheng, — CNBC's Michael Bloom Organizations: JPMorgan, IMVT, Telavant, Merck, Prometheus Locations: Immunovant, IMVT, Roche
In 1818 Mary Shelley published “Frankenstein; or, the Modern Prometheus.”In the novel, Frankenstein brings a creature to life with a "spark of being." Both scientists influenced “Frankenstein.” Shelley incorporated some of Davy’s writings into her novel, and the 1818 and 1831 prefaces both reference Darwin. Mary Wollstonecraft Shelley wrote "Frankenstein" when she was 18 years old. Hulton Archive/Getty ImagesPoet Percy Bysshe Shelley, whom Mary Shelley married the same year she started "Frankenstein," was also fascinated with science. “Could it be electricity?”The electrical experimentsIn her 1831 revised edition of "Frankenstein," Shelley removed the part about lightning and instead referenced galvanism.
Persons: Mary Shelley, , , Frankenstein, Shelley, , Lisa Frankenstein, Victor Frankenstein, Shelley doesn’t, Mary Shelley’s, William Godwin, Erasmus Darwin, Charles ’, Humphry Davy, “ Frankenstein, ” Shelley, Darwin, Mary Wollstonecraft Shelley, Percy Bysshe Shelley, Lord Byron, Percy Shelley, Erasmus Darwin’s, she’d, Byron, Boris Karloff, reenacted Benjamin Franklin ’, Franklin, Michael Faraday, Georg Ohm, Juliet Burba, he'd, Luigi Galvani, he’d, Alessandro Volta, Dominique Jean Larrey, Galvani’s, Giovanni Aldini, Aldini, Thomas Forster, Shelley’s Organizations: Service, Getty, Universal, Obscura Locations: Hulton, Lake Geneva
Family fun, action epics, historical dramas, teen comedy — there’s a little something for everyone among the titles leaving Netflix in the United States in February. ‘Chicken Run’ (Feb. 14)Stream it here. With the long-awaited made-for-Netflix sequel “Chicken Run: Dawn of the Nugget” having hit the service barely six weeks ago, you’d think Netflix would have licensed the original installment for a bit longer. ‘Prometheus’ (Feb. 14)Stream it here. ‘Real Steel’ (Feb. 14)Stream it here.
Persons: Wallace, Gromit, , Ridley Scott, James Cameron, David Fincher, Scott, Theron, Michael Fassbender, It’s, ‘ E.T, Rocky ’, that’s, Roger Ebert, Shawn Levy orchestrates, earnestness, Hugh Jackman Organizations: Netflix Locations: United States
Where to Stream the 2024 Oscar Nominees
  + stars: | 2024-01-23 | by ( Scott Tobias | ) www.nytimes.com   time to read: +2 min
But ultimately, it became a motif that runs the whole way through the film. And I think, to some degree, applying the pressure to Cillian as Oppenheimer that this hearing was applying. Robert Downey Jr. as Lewis Strauss being shot on IMAX black-and-white film. And he’s here talking to Alden Ehrenreich who is absolutely indicative of the incredible ensemble that our casting director John Papsidera put together. And we try to give that as much visibility, grandeur, and glamour to contrast with the security hearing that’s so claustrophobic.
Persons: I’m Christopher Nolan, “ Oppenheimer, Jen Lane, Andrew Jackson, Kai Bird, Martin, , Murphy, Hoyte van Hoytema, Oppenheimer, ” “ We’re, Emily Blunt who’s, Kitty Oppenheimer, Robert Downey Jr, Lewis Strauss, Alden Ehrenreich, John Papsidera Locations: Trinity
Orchid, a startup that tests embryos for genetic diseases, has just raised $12 million. "The way that IVF and embryo screening works today is the amount of information available is really limited," Orchid CEO and cofounder Noor Siddiqui said. Genetic testing has been around for years, but it has been usually limited in the diseases it can identify, which include cystic fibrosis, Bloomberg reported. Orchid produces reports with two types of genetic testing: monogenic and polygenic. The cost of the test depends on the number of embryos that Orchid tests.
Persons: Noor Siddiqui, Siddiqui, Orchid, Dylan, Anne Wojcicki, Fidji Simo, Peter Kraft Organizations: Business, Bloomberg, Prometheus Fund, Starbloom Capital, One Ventures, Los Angeles Times Locations: San Francisco, Pebblebed
What OpenAI’s turmoil is really all about
  + stars: | 2023-11-21 | by ( Allison Morrow | ) edition.cnn.com   time to read: +7 min
OpenAI’s incredible upheaval — with former CEO Sam Altman caught in the middle — could have broad implications for who gets to control the future of artificial intelligence. However, Microsoft has already won the war: It is OpenAI’s most important stakeholder, with a promised $13 billion investment. In the past year, he has become the public face of the industry, and was instrumental in forging OpenAI’s partnership with Microsoft, which began in 2019. Altman, sources say, wanted to move quickly, while the OpenAI board wanted to move more cautiously. Both achievements are possible, and OpenAI’s strange structure — a nonprofit overseeing a for-profit company — was designed to contain AI from destroying humanity.
Persons: Sam Altman, OpenAI, ChatGPT, Altman, Greg Brockman, Satya Nadella, Kara Swisher, , Jason Schloetzer, Gil Luria, Davidson, , Luria, ” Schloetzer, , — CNN’s Clare Duffy Organizations: New, New York CNN, Microsoft, CNBC, CNN, Georgetown’s McDonough School of Business, D.A, Google Locations: New York, Silicon
Marin Ireland Photo: IFC FilmsOne could never faultMary Shelley for a lack of imagination, just a lack of available technology: Her 1818 “Frankenstein” offers no pseudo-scientific explanation for its Creature’s reanimation, only some vague primal force harnessed by the book’s title character. It was the movies, beginning in 1931, that suggested electricity as a means of fusing humans out of spare parts. What is suggested by the remarkable “birth/rebirth” is how Shelley’s story—its mythos, at any rate—can itself be brought back to vibrant life, time after time, by torquing modern medicine into increasingly plausible horror. The Shelley blueprint—which locates the fear factor in every scientific leap that humans make as they inevitably play God—is always paved with good scientific intentions. Rose and Celie mean well.
Persons: Marin, Shelley, Frankenstein ”, Laura Moss, Brendan J, , Rose, Judy Reyes, Organizations: IFC Locations: Marin Ireland
The arousal sparked by uncertainty puts us right where we should be in times of flux, at the raw edge of change. “It means we’re in tune with the environment.”In other words, it pays to lean into uncertainty in times of change. It pays to lean into uncertainty in times of change. Maggie JacksonPeople whose stress levels were most attuned to the game’s fluctuating levels of uncertainty made the most accurate predictions. It may seem surprising that people who can cope with and are even drawn to disquieting not-knowing take such delight in life.
Persons: Maggie Jackson’s, Maggie Jackson Karen Smul, Nicholas Bloom, Maggie Jackson, , Joseph Kable, Robb Rutledge, Rutledge, Todd Kashdan, Paul Silvia, Stephanie Gorka of, disquieting, Nicholas Carleton, Stephen Bird, Stephen Organizations: Prometheus Books, CNN, Stanford University, University of Pennsylvania, Yale University, George Mason University, , University of North, Stephanie Gorka of Ohio State University, University of Regina, Twitter, Facebook Locations: Rhode Island, University of North Carolina, Greensboro, Canada
Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations on strong sales of its blockbuster cancer drug Keytruda, HPV vaccine Gardasil and surprisingly, its Covid drug Lagevrio. Merck lowered its adjusted profit guidance to $1.33 to $1.38 per share, from a previous forecast of $2.95 to $3.05 a share. But that updated outlook reflects an upfront charge of $5.5 billion, or $1.70 per share, related to the company's recent drug collaboration agreement with Daiichi Sankyo. Excluding Lagevrio, pharmaceutical sales grew 9%. The Covid antiviral treatment brought in $640 million in sales for the quarter, up 47% from the third quarter of 2022.
Persons: Merck Organizations: Merck, Prometheus Biosciences, Imago BioSciences, Kelun, Biotech, LSEG, U.S Locations: Japan, Australia
It's an old Silicon Valley philosophy packaged anew: Growth without guardrails. Silicon Valley enters the age of e/accAndreessen and other prominent Silicon Valley figures such as Y Combinator president Garry Tan have quietly added the term e/acc to their social media profiles. In his manifesto, Andreessen calls it "techno-optimism." To some extent, it's a repackaging of what Silicon Valley has always peddled — let us build, grow, and make money without limitations. "Techno-optimists believe growth is progress," Andreessen argues, adding that growth is driven by the progress of technology without hindrance.
Persons: Marc Andreessen, , Andreessen, Andreessen Horowitz, Andy Warhol, Milton Friedman, Prometheus, Y, Garry Tan, pesky ethicists, Carl, Benedikt Frey, Frey Organizations: Service, Silicon, acc Andreessen, acc, Netscape, Oxford Internet Institute Locations: Silicon Valley, digressions, OpenAI
Roche acquired a bowel-disease treatment from Roivant for over $7 billion, the Wall Street Journal reported. AdvertisementAdvertisementRoche's acquisition of a bowel-inflammation treatment delivered a massive windfall for presidential candidate Vivek Ramaswamy's company Roivant, the Wall Street Journal reported. But Roivant's expenses to develop the treatment, which targets an inflammatory protein called TL1A, amounted to just $15 million. And just this month, a $1.5 billion collaboration between Sanofi and Teva Pharmaceuticals was announced for more TL1A treatment. "This is a $15 billion market just in the US, and that's just in [inflammatory bowel disease," Roche chief Teresa Graham told the Journal.
Persons: Roche, Roivant, , Vivek Ramaswamy's, Pfizer, TL1a, that's, " Roche, Teresa Graham Organizations: Wall Street Journal, Pfizer, Service, Telavant Holdings, Food and Drug Administration, Roivant, Prometheus Biosciences, Merck, Sanofi, Teva Pharmaceuticals, pharma Locations: Roivant, Japan
New Roche CEO Thomas Schinecker is keen to restore Roche's battered drug development record after major late-stage trial setbacks in the areas of Alzheimer's and cancer immunotherapy last year. The acquired drug, against inflammatory bowel disease such as ulcerative colitis and Crohn's disease, belongs to a class of new treatments known as anti-TL1A antibodies which has attracted major deal activity in the pharma industry. Merck & Co (MRK.N) in April agreed to buy anti-TL1A antibody developer Prometheus Biosciences for $10.8 billion. Inflammatory bowel disease is a group of chronic gastrointestinal disorders with almost 8 million people diagnosed worldwide and 80% of all individuals not experiencing lasting remission, Roche said. "We strongly believe this novel TL1A directed antibody has the transformational potential to make a significant difference for patients living with inflammatory bowel disease and potentially other diseases," said Roche CEO Schinecker.
Persons: drugmaker Roche, Arnd, New Roche, Thomas Schinecker, Schinecker, Roche, John Revill, Ludwig Burger, Friederike Heine, Jason Neely Organizations: REUTERS, Roivant Holdings, Pfizer Inc, pharma, Sanofi, Merck & Co, Prometheus Biosciences, Thomson Locations: Basel, Switzerland, ZURICH, FRANKFURT, Swiss, U.S, Japan, Zurich, Frankfurt
Roche's $7 bln deal is pricey and partial cure
  + stars: | 2023-10-23 | by ( ) www.reuters.com   time to read: +2 min
Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration shot January 22, 2016. REUTERS/Dado Ruvic/Illustration Acquire Licensing RightsNEW YORK, Oct 23 (Reuters Breakingviews) - Roche (ROG.S) has taken a small step towards curing its drug pipeline problem. JPMorgan analysts estimate that the drug’s U.S. sales could peak at 2.4 billion Swiss francs ($2.7 billion), but will take until 2037 to get there, assuming a 2028 launch. Analysts expect Roche’s pharmaceutical division to generate revenue of almost 45 billion Swiss francs this year, according to estimates compiled by LSEG. With expected free cash flow of around 16 billion Swiss francs this year and next, Roche can afford to buy a little more diversification.
Persons: Roche, Dado Ruvic, Thomas Schinecker, Peter Thal Larsen, Jean, Pierre Mustier, Atos, Jonathan Guilford, Aditya Sriwatsav Organizations: REUTERS, Reuters, Pfizer, U.S, New, JPMorgan, Merck, Prometheus Biosciences, Analysts, LSEG, X, News Corp, Thomson Locations: Swiss, U.S
Tuesday General Motors is set to report earnings before the bell, followed by a call at 8:30 a.m. Coca-Cola is set to report earnings in the premarket, with a call slated for 8:30 .am. Wednesday Boeing is set to report earnings in the premarket, with leadership scheduled to hold a call at 10:30 a.m. Ford Motor is set to report earnings after the bell, followed by a conference call at 5 p.m. This quarter: The e-commerce giant is expected to report earnings per share growth of more than 100%, according to LSEG.
Persons: Michael Wayland, they'll, Andrea Teixeira, MSFT, Jordan Novet, GOOGL, Justin Post, MRK, Goldman Sachs, Chris Shibutani, Keytruda, Ford, AMZN, Doug Anmuth, — CNBC's Michael Bloom Organizations: Big Tech, Microsoft, Meta, Wall, CNBC, GM, LSEG, United Auto Workers, Investment Group, Coca, U.S, Activision, Wednesday Boeing, Boeing, Management, Bank of America, IBM, Merck, Ford, UAW, Detroit, JPMorgan Locations: Missouri, EVs, China, Apptio
The atomic bomb may be, for the soldiers and politicians, a powerful strategic tool in war and diplomacy. He snatched a spark of quantum insight from those divinities and handed it to Harry S. Truman and the U.S. Army Air Forces. (The notable exception is Edward Teller, the father of the hydrogen bomb and as such another potential Prometheus.) Like the original Prometheus, Oppenheimer survives his disgrace, and ends the movie as a flawed, haunted, regretful creature, carrying a flicker of inextinguishable, theoretical guilt. A.I., on the other hand, seems newly sprung from science fiction, and especially terrifying because we can’t quite grasp what it will become.
Persons: Oppenheimer, “ Oppenheimer, , Oppenheimer wasn’t, Niels Bohr, Erwin Schrödinger, Werner Heisenberg, Harry S, Truman, , Edward Teller, von Neumann Organizations: U.S . Army Air Forces Locations: Hiroshima, Nagasaki
This AI company wants to help you control your dreams
  + stars: | 2023-10-04 | by ( Hayden Field | ) www.cnbc.com   time to read: +2 min
It's a tech startup building what the company calls the "world's first wearable device for stabilizing lucid dreams." Lucid dreams occur when a person sleeping becomes aware they're dreaming and may be able to control parts of the dream. Humane AI, a company founded in 2017 by former Apple employees, debuted its wearable — the AI Pin — on the runway last week at Paris Fashion Week. And famed iPhone designer Jony Ive and OpenAI's Sam Altman are also reportedly discussing an AI hardware project. The co-founders have the type of lofty dreams typical of a modern-era tech startup, with Wollberg comparing the company to OpenAI.
Persons: Eric Wollberg, Wesley Berry, Wollberg, Berry, Grimes, BoxGroup, Card79, Jony, Sam Altman, Prometheus Organizations: a16z's Scout Fund, Plaid, Elon, Apple, Paris Fashion, Donders Institute for Brain, Radboud University Locations: Netherlands
Corbis/Getty ImagesScholar Teresia Teaiwa famously critiqued the bikini as instrumental to depoliticizing and concealing the effects of nuclear weapons in the Pacific. Britain and France would later begin their own nuclear weapons programs on Indigenous lands and waters in Australia and French Occupied Polynesia, among others. The US began detonating nuclear bombs at the Nevada Test Site in 1951, garnering nearby Las Vegas the nickname Atomic City. Atomic playboys have aestheticized nuclear weapons as sexy — but still safe — since their very existence. Nolan prolongs the time between the flash and the blast, allowing Oppenheimer’s words to hang in unnerving suspension.
Persons: Rebecca H, Hogue, Barbie ”, “ Oppenheimer, “ Barbie ”, Barbenheimer, Hogue Rebecca H, Baker, ” Rita Hayworth, Gilda, Hayworth, — Jacques Heim’s, Louis Réard, Corbis, Teresia Teaiwa, Lee A, Merlin, SpongeBob, Bert, Turtle, Walt, William Blandy, , Christopher Nolan’s “ Oppenheimer, Cillian Murphy, Nolan, Oppie, Ernest Lawrence, Josh Hartnett, Jean Tatlock, Florence Pugh, Kitty Oppenheimer, Emily Blunt, Tatlock, Oppenheimer, J, Robert Oppenheimer, Christopher Nolan's, Melinda Sue Gordon, Nolan prolongs, “ Gilda, , Nolan bifurcates “ Oppenheimer ”, ” “ Oppenheimer, Barbie, Margot Robbie, , Ken, Ryan Gosling, , Barbie’s, Mike ”, Edward Teller, “ It’s, Teller, “ Oppenheimer ” Organizations: Dartmouth College’s Society of Fellows, Mahindra Humanities Center, Harvard University, CNN, Warner Brothers Discovery, Universal, Trinity, Crossroads, Getty, Atomic Energy Commission, US, Las, Atomic, National Atomic Testing, Los, Communist Party, American, Twitter Locations: Pacific, Oceania, New Mexico, Hiroshima, Nagasaki, Marshall Islands, Kiribati, Northern Paiute, Western, Nevada, Amchitka , Alaska, Bikini Atoll, Britain, France, Australia, French, Las Vegas, Las, Playthings, Los Alamos, Japan, American, iconicity, Alamos
Credit Suisse refreshed its "top of the crop" stock picks for August, betting on some big-name stocks as investors continue to feed the markets with optimism. Credit Suisse recently highlighted several stocks the bank's analysts think can outperform this month. "It is increasingly clear that greater service levels in the form of faster delivery is leading to consumers assigning a higher value to Prime" memberships, Credit Suisse said. Credit Suisse also named electronics manufacturer Flex Ltd. as a top pick. Credit Suisse assigned a $126 price target on Merck, which implies 20% appreciation from Friday's closing price.
Persons: Stocks, Stephen Ju, Amazon's, Ju, Shannon Cross, Flex, Cross, Trung Huynh, Merck, — CNBC's Michael Bloom Organizations: Suisse, Credit Suisse, Amazon, Flex, Merck, Prometheus Biosciences
The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion. Sales of Gardasil, which prevents cancers caused by HPV, surged 47% to $2.5 billion, also well above Wall Street estimates of $2.1 billion. There is room for further Gardasil growth as its use expands into treating males and moves into smaller cities, he added. Despite those challenges, Merck raised its full-year sales forecast to $58.6 to $59.6 billion, from its prior view of $57.7 billion to $58.9 billion.
Persons: Brendan McDermid, Merck, Rob Davis, Davis, Keytruda, Caroline Litchfield, Litchfield, Bill Smead, Prometheus, drugmaker, Michael Erman, Leroy Leo, Bill Berkrot Organizations: Merck, Co, REUTERS, Reuters Connect Companies Merck, Merck & Co, Keytruda, Prometheus Biosciences, Analysts, Prometheus, Smead Capital Management, drugmaker, Thomson Locations: Rahway , New Jersey, U.S, United States, China, Europe, Germany, New York, Bengaluru
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMerck CEO Rob Davis on Q2 results: We continue to see phenomenal growthMerck chairman and CEO Rob Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil, but posted a quarterly loss due to its acquisition of the biotech company Prometheus Biosciences earlier this year.
Persons: Rob Davis Organizations: Merck, Prometheus Biosciences
Companies Merck & Co Inc FollowAug 1 (Reuters) - Merck & Co (MRK.N) posted better-than-expected second-quarter sales on Tuesday on strong demand for its two top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil. Shares of Merck rose about 2% at $108.45 in premarket trading after the company also raised its full-year revenue forecast. Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion. Sales of Gardasil, which prevents cancers caused by HPV, surged 47% to $2.5 billion, also well above Wall Street estimates of $2.1 billion. Merck said it now expects full-year sales of $58.6 to $59.6 billion, up from its prior view of $57.7 billion to $58.9 billion.
Persons: Merck, Rob Davis, Davis, Keytruda, Cantor Fitzgerald, Louise Chen, Prometheus, drugmaker, Michael Erman, Leroy Leo, Bill Berkrot Organizations: Merck, Co, Merck & Co, Merck's, Prometheus Biosciences, Analysts, Prometheus, Thomson Locations: United States, China, U.S, New York, Bengaluru
Merck on Tuesday reported second-quarter revenue that topped expectations on strong sales of its blockbuster cancer drug Keytruda and HPV vaccine Gardasil. The pharmaceutical giant posted a quarterly loss, however, due to charges associated with the company's acquisition of Prometheus Biosciences earlier this year. Merck swung to a net loss of $5.98 billion, or $2.35 per share, from a net income of $3.94 billion, or $1.55 per share, during the year-earlier period. The loss reflects a $10.2 billion, or $4.02 per share, charge related to the company's acquisition of Prometheus, which specializes in treatments for autoimmune diseases. "What you really see...was long sustained underlying growth, and it was driven by oncology and vaccines, and the Gardasil franchise in vaccines," Merck CEO Robert Davis said in an interview on CNBC's "Squawk Box" on Tuesday.
Persons: Merck, Robert Davis Organizations: Merck, Prometheus Biosciences, Prometheus, Refinitiv Locations: U.S
This quarter: Analysts polled by FactSet expect Merck to post a loss for the first quarter. Starbucks is set to report earnings after the bell, with management slated to hold a call at 5 p.m. This quarter: Analysts polled by FactSet expect double-digit earnings growth quarter over quarter. What history shows: Bespoke data shows Amazon earnings exceed earnings expectations 62% of the time. Apple is set to report earnings after the close, followed by a call at 5 p.m.
Persons: Goldman Sachs, Annika Kim Constantino, Merck, Merck's, Joe Biden's, SBUX, Bank of America's Sara Senatore, Senatore, Albert Bourla, , They're, AMZN, FactSet, Annie Palmer, Morgan Stanley, Erik Woodring, — CNBC's Michael Bloom Organizations: Netflix, Merck, Apple, FactSet, CNBC, Prometheus Biosciences, Investment, Bank of America's, Pfizer, Management, Amazon Web Services, IDC Locations: China, 2Q23, New York, Carolina, Friday's
Total: 25